Asian Pacific Journal of Cancer Prevention

  • 제15권2호
  • /
  • Pages.813-818
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Institutional Experience of Interstitial Brachytherapy for Head and Neck Cancer with a Comparison of High- and Low Dose Rate Practice

  • Mohanti, Bidhu Kalyan (Department of Radiation Oncology, All India Institute of Medical Sciences) ;
  • Sahai, Puja (Department of Radiation Oncology, All India Institute of Medical Sciences) ;
  • Thakar, Alok (Department of Otolaryngology and Head-Neck Surgery, All India Institute of Medical Sciences) ;
  • Sikka, Kapil (Department of Otolaryngology and Head-Neck Surgery, All India Institute of Medical Sciences) ;
  • Bhasker, Suman (Department of Radiation Oncology, All India Institute of Medical Sciences) ;
  • Sharma, Atul (Department of Medical Oncology, All India Institute of Medical Sciences) ;
  • Sharma, Seema (Department of Radiation Oncology, All India Institute of Medical Sciences) ;
  • Bahadur, Sudhir (Department of Otolaryngology and Head-Neck Surgery, All India Institute of Medical Sciences)
  • 발행 : 2014.01.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Aims: To describe our institutional experience with high dose rate (HDR) interstitial brachytherapy (IBT) compared with previously reported results on the low dose rate (LDR) practice for head and neck cancer. Materials and Methods: Eighty-four patients with oral cavity (n=70) or oropharyngeal cancer (n=14) were treated with 192Ir HDR-IBT. Seventy-eight patients had stage I or II tumour. The patients treated with IBT alone (n=42) received 39-42 Gy/10-14 fractions (median=40 Gy/10 fractions). With respect to the combination therapy group (n=42), prescription dose comprised of 12-18 Gy/3-6 fractions (median=15 Gy/5 fractions) for IBT and 40-50 Gy/20-25 fractions (median=50 Gy/25 fractions) for external radiotherapy. Brachytherapy was given as 2 fractions per day 6 hours apart with 4 Gy per fraction for monotherapy and 3 Gy per fraction for combination therapy. Results: Four patients were not evaluable in the analysis of outcome. The primary site relapse rates were 23.8% (10/42) and 68.4% (26/38) in patients treated with IBT alone and combination therapy, respectively (p<0.001). Salvage surgery was performed in 19 patients. The 5-year local control rate was estimated at 62% and the disease-free survival (DFS) rate at 52% for all patients. Local control with respect to T1 and T2 tumours was 84% and 42%, respectively. Conclusions: Our present series on HDR-IBT and the previous report on LDR-IBT for head and neck cancer demonstrated similar DFS rates at 5 years (52%). The rate of regional failure in node-negative patients was <20% in both of our series. HDR-IBT offers similar results to LDR-IBT for head and neck cancer.

키워드

참고문헌

  1. Bartochowska A, Wierzbicka M, Skowronek J, Leszczynska M, Szyfter W (2012). High-dose-rate and pulsed-dose-rate brachytherapy in palliative treatment of head and neck cancers. Brachytherapy, 11, 137-43. https://doi.org/10.1016/j.brachy.2011.09.006
  2. Borgemeester MC, van den Brekel MW, van Tinteren H, et al (2008). Ultrasound-guided aspiration cytology for the assessment of the clinically N0 neck: factors influencing its accuracy. Head Neck, 30, 1505-13. https://doi.org/10.1002/hed.20903
  3. Concato J, Shah N, Horwitz RI (2000). Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med, 342, 1847-92.
  4. Cox JD, Stetz J, Pajak TF (1995). Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31, 1341-6. https://doi.org/10.1016/0360-3016(95)00060-C
  5. Ganly I, Patel S, Shah J (2012). Early stage squamous cell cancer of the oral tongue-clinicopathologic features affecting outcome. Cancer, 118, 101-11. https://doi.org/10.1002/cncr.26229
  6. Ghadjar P, Bojaxhiu B, Simcock M, et al (2012). High doserate versus low dose-rate brachytherapy for lip cancer. Int J Radiat Oncol Biol Phys, 83, 1205-12. https://doi.org/10.1016/j.ijrobp.2011.09.038
  7. Glatzel M, Buntzel J, Schroder D, Kuttner K, Frohlich D (2002). High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer. Laryngoscope, 112, 1366-71. https://doi.org/10.1097/00005537-200208000-00008
  8. Greene FL, Page DL, Fleming ID, et al (2002). AJCC Cancer Staging Manual. 6th edn. Springer-Verlag, New York.
  9. Guinot JL, Santos M, Tortajada MI, et al (2010). Efficacy of high-dose-rate interstitial brachytherapy in patients with oral tongue carcinoma. Brachytherapy, 9, 227-34. https://doi.org/10.1016/j.brachy.2009.10.003
  10. Inoue T, Inoue T, Yoshida K, et al (2001). Phase III trial of highvs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer. Int J Radiat Oncol Biol Phys, 51, 171-5.
  11. Kakimoto N, Inoue T, Inoue T, et al (2003). Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. Radiother Oncol, 68, 123-8. https://doi.org/10.1016/S0167-8140(03)00055-0
  12. Masuda M, Kuratomi Y, Shiratsuchi H, et al (2000). Decreased CD44H expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. Head Neck, 22, 662-5. https://doi.org/10.1002/1097-0347(200010)22:7<662::AID-HED4>3.0.CO;2-O
  13. Mazeron JJ, Noel G, Simon JM (2002). Head and neck brachytherapy. Semin Radiat Oncol, 12, 95-108. https://doi.org/10.1053/srao.2002.28668
  14. Mazeron JJ, Ardiet JM, Haie-Meder C, et al (2009). GECESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol, 91, 150-6. https://doi.org/10.1016/j.radonc.2009.01.005
  15. Mohanti BK, Bansal M, Bahadur S, et al (2001). Interstitial brachytherapy with or without external beam irradiation in head and neck cancer: Institute Rotary Cancer Hospital experience. Clin Oncol, 13, 345-52.
  16. Nag S, Cano ER, Demanes DJ, Puthawala AA, Vikram B; American Brachytherapy Society (2001). The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys, 50, 1190-8. https://doi.org/10.1016/S0360-3016(01)01567-X
  17. Nose T, Koizumi M, Nishiyama K (2004). High-dose-rate interstitial brachytherapy for oropharyngeal carcinoma: results of 83 lesions in 82 patients. Int J Radiat Oncol Biol Phy, 59, 983-91. https://doi.org/10.1016/j.ijrobp.2003.12.015
  18. Okura M, Aikawa T, Sawai NY, Iida S, Kogo M (2009). Decision analysis and treatment threshold in a management for the N0 neck of the oral cavity carcinoma. Oral Oncol, 45, 908-11. https://doi.org/10.1016/j.oraloncology.2009.03.013
  19. Soares HP, Kumar A, Daniels S, et al (2005). Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA, 293, 970-8. https://doi.org/10.1001/jama.293.8.970
  20. Umeda M, Komatsubara H, Ojima Y, et al (2005). A comparison of brachytherapy and surgery for the treatment of stage I-II squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg, 34, 739-44. https://doi.org/10.1016/j.ijom.2005.02.015
  21. Urashima Y, Nakamura K, Shioyama Y, et al (2006). Long-term functional outcome of brachytherapy for carcinoma of the mobile tongue: focus on the atrophic change of irradiated tongue. Jpn J Clin Oncol, 36, 681-7. https://doi.org/10.1093/jjco/hyl099
  22. van Wilgen CP, Dijkstra PU, van der Laan BF, Plukker JT, Roodenburg JL (2004). Morbidity of the neck after head and neck cancer therapy. Head Neck, 26, 785-91. https://doi.org/10.1002/hed.20008
  23. Wang X, Liu R, Ma B, et al (2010). High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev, 7, 7563.
  24. Wensing BM, Merkx MA, De Wilde PC, Marres HA, Van den Hoogen FJ (2010). Assessment of preoperative ultrasonography of the neck and elective neck dissection in patients with oral squamous cell carcinoma. Oral Oncol, 46, 87-91. https://doi.org/10.1016/j.oraloncology.2009.11.015
  25. Yamazaki H, Inoue T, Yoshida K, et al (2003). Brachytherapy for early oral tongue cancer: low dose rate to high dose rate. J Radiat Res, 44, 37-40. https://doi.org/10.1269/jrr.44.37
  26. Yamazaki H, Inoue T, Yoshida K, et al (2004). Lymph node metastasis of early oral tongue cancer after interstitial radiotherapy. Int J Radiat Oncol Biol Phys, 58, 139-46. https://doi.org/10.1016/S0360-3016(03)01459-7